High prices for combination regimens will translate to high revenues, despite the introduction of generics in the mid-term future. The increased use of Trikafta will offset the decrease in revenues caused by generics over the forecast period. 

The first CFTR modulator triplet, Trikafta, is approved in patients with at least one F508del mutation regardless of their second mutation. Despite its late approval, Trikafta is the only CFTR modulator approved for F508del heterozygous patients, and its substantial improvement in lung function over both Symdeko and Orkambi in F508del homozygous patients has allowed it to capture the majority of the CF patient population. Although there are alternative triplet CFTR modulator combinations in development, it is likely Trikafta’s dominance of the market will remain unchallenged. 

This Datamonitor Healthcare report contains a Disease Analysis module.